Team
health

SCORAD Calculator

The SCORAD (SCORing Atopic Dermatitis) index quantifies eczema severity across three dimensions: extent of skin involvement, intensity of clinical signs, and subjective symptoms. Clinicians use this 0–103 point scale to track disease progression, evaluate treatment response, and standardise severity classification. Understanding your SCORAD score helps guide management decisions, from emollient selection to systemic therapy consideration.

Last updated:

Creators Łucja Zaborowska, MD, PhD
3,880 people find this calculator helpful

What Is Atopic Dermatitis?

Atopic dermatitis is a chronic inflammatory skin condition characterised by a compromised skin barrier and heightened immune reactivity. Unlike healthy skin, which maintains a robust protective lipid layer, atopic dermatitis disrupts this defence mechanism through defective filaggrin—a structural protein that binds epidermal cells. Without adequate filaggrin, irritants, allergens, and moisture penetrate deeper into the epidermis, triggering inflammation and water loss.

The condition clusters with other atopic diseases: asthma, allergic rhinitis, and food allergies often run alongside eczema in affected families. Genetic predisposition is central—if both parents have atopic dermatitis, a child has roughly a 60–80% risk. Environmental factors amplify flares: hard water, fragrances, stress, temperature swings, and low humidity all accelerate deterioration. Unlike acute dermatitis, atopic dermatitis is persistent, though symptom severity fluctuates with seasons and individual triggers.

SCORAD Scoring Formula

The SCORAD index combines three equally weighted domains: affected body surface area (A), objective clinical signs (B), and subjective symptoms (C). Each domain contributes proportionally to the final score, which ranges from 0 (clear) to 103 (severe).

SCORAD = (A ÷ 5) + (7B ÷ 2) + C

where:

A = Head + Neck + Upper limbs + Trunk + Lower limbs + Genitals

B = Redness + Swelling + Oozing + Scratch marks + Thickening + Dryness

C = Pruritus + Insomnia (last 3 days)

  • A — Percentage of body surface area affected (0–100%)
  • B — Sum of six clinical signs, each scored 0–3 (total 0–18)
  • C — Patient-reported itch intensity and sleep loss over 72 hours, each 0–10 (total 0–20)

How to Use the SCORAD Calculator

Step 1: Map affected areas. The calculator divides the body into seven zones with standardised percentages: head and neck (9%), each upper limb (9%), anterior trunk (18%), back (18%), each lower limb (18%), and genitals (1%). Estimate the percentage of each zone covered by eczema lesions. The rule of nines provides rough guidance; hover over region labels for precise anatomical breakdowns.

Step 2: Score objective signs. Examine active lesions within affected areas. Rate redness (erythema), swelling (oedema), oozing or crusting, excoriations, lichenification (thickening), and dryness on a 0–3 scale, where 0 = absent and 3 = severe.

Step 3: Record subjective symptoms. Ask the patient about itch intensity and sleep disruption over the preceding three days on a 0–10 scale, where 0 = no symptoms and 10 = worst imaginable.

Step 4: Calculate. The calculator automatically computes A, B, and C, then applies the SCORAD formula to produce the final index.

Atopic Dermatitis Severity Classification

SCORAD score interpretation:

  • 0–15: Mild. Minimal visible lesions; symptoms rarely disrupt daily activity.
  • 16–50: Moderate. Widespread involvement or intense signs; symptoms affect sleep or function.
  • ≥51: Severe. Extensive body surface involvement and/or marked clinical signs; significant quality-of-life impact.

A rising SCORAD across visits signals disease escalation and may prompt intensification of topical corticosteroids, calcineurin inhibitors, or referral to systemic therapy. Conversely, a falling score confirms treatment efficacy. The SCORAD is particularly valuable in clinical trials and specialist settings where objective severity measurement informs evidence-based decisions.

Common Pitfalls When Scoring SCORAD

Accurate SCORAD assessment requires attention to anatomical precision and consistent clinical evaluation.

  1. Overestimating affected area — Clinicians often round up scattered lesions to inflated percentages. Use the body zone map systematically: if only 20% of the lower leg has dermatitis but 80% of the forearm is affected, enter these separately rather than approximating a global body surface area.
  2. Conflating inflammation with dryness — Dryness exists independent of active inflammation. A patient may have minimal redness (0–1) but severe xerosis (3) from the skin barrier defect itself. Score these objectively: scale 0–3 reflects visible dryness regardless of other signs.
  3. Relying solely on patient-reported itch without context — Pruritus scoring (0–10) captures itch intensity but not causation. Scratching-induced damage elevates the scratch-marks score (B), creating a circular link. Document whether itch is baseline dermatitis or secondary to irritant contact or stress during the assessment period.
  4. Forgetting temporal specificity for symptoms — The calculator specifies pruritus and insomnia over the last three days. Scores from yesterday's flare or last week's poor sleep misalign with current disease state and lead to score drift. Clarify timing with the patient before entry.

Frequently Asked Questions

What does a SCORAD score of 50 mean?

A SCORAD of 50 places a patient in the moderate-to-severe boundary. This typically indicates 40–60% body surface involvement with moderate clinical signs (redness, oozing, thickening) and substantial subjective symptoms (itch often 7–10, sleep loss present). Such a score warrants discussion of step-up therapy: potent topical corticosteroids, calcineurin inhibitors, or referral to dermatology if not already under specialist care.

Can SCORAD be used to monitor home treatment response?

SCORAD is clinician-administered and requires objective examination, so it is not designed for self-monitoring between visits. However, patients can track their own itch intensity, sleep quality, and rough skin appearance at home, then report these observations at scheduled follow-ups. Formal SCORAD reassessment at 4–12 week intervals (depending on treatment intensity) provides objective evidence of improvement or deterioration.

Why does the SCORAD formula weight B (clinical signs) more heavily than A (area)?

The formula allocates 7B/2, making clinical signs proportionally more influential than body area alone. This weighting reflects the clinical reality that a small region with severe inflammation (redness, oozing, excoriation) causes greater morbidity than a large area with mild erythema alone. A patient with eczema on 20% of the body but intense signs may score higher than someone with 50% involvement but minimal inflammation.

Is SCORAD better than other eczema scoring tools?

SCORAD is one of over 20 validated eczema severity scales; its suitability depends on context. EASI (Eczema Area and Severity Index) omits subjective symptoms and suits quick clinical assessments. POEM (Patient-Oriented Eczema Measure) prioritises patient-reported outcomes for research. SCORAD balances objective and subjective dimensions, making it the gold standard in many dermatology trials and specialist practice, though choice ultimately hinges on study design or clinical workflow.

What lifestyle changes reduce SCORAD scores most effectively?

Consistent skin barrier repair—daily emollient application immediately after bathing—is foundational. Avoiding specific triggers (hard water, fragrances, wool, excessive heat, stress) reduces flare frequency and severity. Maintaining 40–60% indoor humidity, wearing soft cotton clothing, and managing stress through sleep, exercise, or mindfulness have demonstrated secondary benefits in eczema management. Dietary omega-3 supplementation and vitamin D repletion show modest benefit in some cohorts but are adjunctive to topical and systemic therapies.

How often should SCORAD be reassessed during treatment?

Frequency depends on disease severity and treatment intensity. Mild disease may warrant reassessment every 8–12 weeks, while moderate-to-severe cases or newly initiated systemic therapy should be scored every 2–4 weeks to detect response early. In clinical trials, SCORAD is often measured at baseline, week 4, 8, 12, and beyond. More frequent assessment risks measurement error; less frequent assessment may miss deterioration warranting intervention adjustment.

More health calculators (see all)

ICH Calculator PECARN Calculator GAD-7 Calculator Period Calculator Opioid Conversion Calculator Dog Walking Benefits Calculator Vaccine Queue Northern Ireland Calculator Twins Calculator